RE:RE:RE:Can’t believe some folks sold on today’s news! We have to beat the competition by a nice margin to be number one and that IMO should not be too hard given that the present competition single agents is 17%CR for Vicinium, 19%CR for Keytruda, and 24% CR for Adstiladrin. We have the potential to make these look like placebos IMO, however we still need more data and for sure we will be able to tell after the next 11 patients are treated. As long as they are all given proper Optimized treatment. The competition's CR rate decreases at 6 months as ours is increasing which is good to see and let's hope it increases even further as we get more data.
gojotv! wrote: Anyone who isn't ecstatic to see a 45% "complete response" rate PLUS a 22% "partial response" rate PLUS 22% more "to be determined"...
Must be allergic to money.
Anyone who sold... *smh
Pull your "stop losses, boys and girls, the manipulators are out and this is their last chance for cheap shares! Don't let 'em get yours!
(IMNSHO, of course! lol)
Pandora wrote: livermore2 wrote: The price recovery definitely paints it was a shake.
Put this one away for a year or two - just like wine, it should get better with age!
Yep, been doing that for 6 years now! Drank all my wine and more in the meantime! :-))